Posts

Indian Pharma IP Trends: Biophore’s Patent Strategy, Oral Semaglutide SNAC Battles & Lenacapavir Oppositions

Image
  Biophore India Pharmaceuticals: Generic Patent Filing Strategy (2024–2026) Between October 2024 and November 2026, Biophore India Pharmaceuticals published 28 patent families—matching industry giant Cipla’s filing volume during the same timeframe despite operating at a much smaller revenue scale . Rather than pursuing new chemical entities, Biophore’s intellectual property portfolio functions as a targeted generic-launch pipeline designed to secure early market entry and freedom to operate . Portfolio Breakdown: Over half (54%, or 15 families) protect active pharmaceutical ingredient (API) manufacturing processes, 25% (7 families) cover finished formulations, and 21% (6 families) claim solid forms or salts . Therapeutic Focus: Filings prioritise central nervous system (CNS) disorders (7 families), rare diseases (7 families), and oncology (6 families) . High-Value Targets: Biophore has layered multiple patents around niche US-approved drugs (2021–2023) such as elacest...

API & IP Brief: FDA CGT Approvals Review, Sodium Thiosulfate Patent Ruling & Biopharma Updates

Image
API & IP Intelligence Brief: FDA Competitive Generic Therapy (CGT) Review & Purity Patent Rulings Target Keywords: Competitive Generic Therapy, CGT exclusivity, FDA ANDA approvals, Zydus Lifesciences, Amneal lanreotide, Hope Medical v Accord, sodium thiosulfate patent, API purity specifications, Paragraph IV litigation, Teva R&D Day . Six-Month FDA Competitive Generic Therapy (CGT) Review (Apr – Oct 2026) Between April 28 and October 19, 2026, the FDA approved 45 Abbreviated New Drug Applications (ANDAs) holding Competitive Generic Therapy (CGT) designations, up from 41 in the prior six-month period . However, only 12 approvals (27%) qualified for 180-day CGT market exclusivity, continuing a downward eligibility trend from 71% in 2019 to 26% so far in 2026 . Under Section 506H of the FD&C Act, CGT incentivises entry into off-patent or sole-source drugs facing inadequate generic competition . To unlock 180-day exclusivity, the first approved applicant must have ha...